Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana; Ancistrocladus ealaensis; , Targeting Pancreatic Cancer Cells by Tshitenge, Dieudonné Tshitenge et al.
Ealamines A−H, a Series of Naphthylisoquinolines with the Rare
7,8′-Coupling Site, from the Congolese Liana Ancistrocladus
ealaensis, Targeting Pancreatic Cancer Cells
Dieudonne ́ Tshitenge Tshitenge,†,‡,§ Torsten Bruhn,†,⊥ Doris Feineis,† David Schmidt,†
Virima Mudogo,∥ Marcel Kaiser,¶,○ Reto Brun,¶,○ Frank Würthner,† Suresh Awale,*,#
and Gerhard Bringmann*,†
†Institute of Organic Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
‡Faculty of Pharmaceutical Sciences, University of Kinshasa, B.P. 212 Kinshasa XI, Democratic Republic of the Congo
§Medicinal Chemistry, Bayer AG, Pharmaceuticals, Aprather Weg 18a, D-42096 Wuppertal, Germany
⊥Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, D-10589 Berlin, Germany
∥Faculte ́ des Sciences, Universite ́ de Kinshasa, B.P. 202, Kinshasa XI, Democratic Republic of the Congo
¶Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland
○University of Basel, Petersplatz 1, CH-4003 Basel, Switzerland
#Division of Natural Drug Discovery, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
*S Supporting Information
ABSTRACT: From the twigs and leaves of the Central African liana Ancistrocladus ealaensis (Ancistrocladaceae), a series of ten
7,8′-coupled naphthylisoquinoline alkaloids were isolated, comprising eight new compounds, named ealamines A−H (4a, 4b,
5−10), and two known ones, 6-O-demethylancistrobrevine A (11) and yaoundamine A (12), which had previously been found
in related African Ancistrocladus species. Only one of the new compounds within this series, ealamine H (10), is a typical
Ancistrocladaceae-type alkaloid, with 3S-conﬁguration at C-3 and an oxygen function at C-6, whereas seven of the new alkaloids
are the ﬁrst 7,8′-linked “hybrid-type” naphthylisoquinoline alkaloids, i.e., 3R-conﬁgured and 6-oxygenated in the
tetrahydroisoquinoline part. The discovery of such a broad series of 7,8′-coupled naphthyltetrahydroisoquinolines is
unprecedented, because representatives of this subclass of alkaloids are normally found in Nature quite rarely. The
stereostructures of the new ealamines were assigned by HRESIMS, 1D and 2D NMR, oxidative degradation, and experimental
and quantum-chemical ECD investigations, andin the case of ealamine A (4a)also conﬁrmed by X-ray diﬀraction analysis.
Ealamines A−D exhibited distinctand speciﬁcantiplasmodial activities, and they displayed pronounced preferential
cytotoxic eﬀects toward PANC-1 human pancreatic cancer cells in nutrient-deprived medium, without causing toxicity under
normal, nutrient-rich conditions, with ealamine C (5) as the most potent agent.
Naphthylisoquinoline alkaloids1−3 are the only di- andtetrahydroisoquinoline natural products that are not, as
usual, built up from aromatic amino acids,4 but from acetate/
malonate units, following a novel, polyketidic pathway to
isoquinolines in plants.5 Their two molecular halves, the
naphthalene and the isoquinoline subunits, are formed
separately, both from joint polyketide precursors, and are
connected to each other at a quite late stage of the biosynthetic
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route,1,5,6 by phenol-oxidative cross-coupling, which occurs
ortho or para relative to free phenolic oxygen functions. Based
on this principle, eight C,C-coupling types are imaginable, of
which seven (viz., 5,1′, 5,3′, 5,8′, 7,1′, 7,3′, 7,6′, and 7,8′) have
so far been discovered in Nature.1−3
The Congolese liana Ancistrocladus ealaensis J. Leónard7,8 is
a rich source of structurally diverse naphthylisoquinoline
alkaloids.9−12 Its metabolic proﬁle diﬀers completely from
those of the three other known taxa likewise endemic to the
Congo Basin, A. congolensis,13,14 A. likoko,15−18 and A.
ileboensis,19,20 but also from the proﬁles of further, botanically
yet undescribed Ancistrocladus lianas21−27 recently discovered
in the rainforests of the Democratic Republic of the Congo.
From A. ealaensis, a series of unusual heterodimers,10−12
belonging to four subgroups of dimers, have been isolated,
representing an unprecedented plethora of all these alkaloid
types in the same plant. Among these compounds were four
highly unsymmetric 6′,1″-coupled mbandakamines11 consist-
ing of two 5,8′-coupled monomers with three consecutive
stereogenic axes identiﬁed along with a nearly symmetric
michellamine-type dimer,10 likewise built up from two 5,8′-
coupled monomers, but linked via a freely rotating central
6′,6″-axis. Unprecedented was the discovery of seven oxygen-
bridged mbandakamine-type dimers, named cyclombandak-
amines,12 featuring an unusual condensed cage-like polycyclic
backbone. In addition, three unusual heterodimers such as
ealapasamine C (1)9 (Figure 1) have been found in the leaves
of A. ealaensis, containing two diﬀerent biaryl moieties, viz., a
5,8′-coupled naphthylisoquinoline and a 7,8′-linked portion,
with a central 6′,6″-coupled binaphthalene core.
Most of the Central African Ancistrocladus species produce
predominantly 5,8′-linked mono- and dimeric naphthylisoqui-
noline alkaloids.13−18,23−29 More than 90 alkaloids of this
subclass have so far been isolated, among them typical
Ancistrocladaceae-type1,3 compounds such as ancistroealaine
A (2),9,23,26 with the S-conﬁguration at C-3 and an oxygen
function at C-6. In addition, a noticeable number of “hybrid-
type”1,3 naphthylisoquinolines have been identiﬁed such as
ancistroealaine C (3)11,25 (Figure 1), i.e., likewise oxygenated
at C-6, but with an R-conﬁguration at C-3. In contrast to the
numerous 5,8′-coupled naphthylisoquinoline alkaloids, their
7,8′-linked analogues are far less common in Nature; only 20
such compounds (15 monomers19,30−32 and ﬁve dimers10,33,34)
have been detected so far in Ancistrocladus plants.
We report herein the isolation and structural elucidation of
an unusual series of eight new 7,8′-coupled naphthylisoquino-
line alkaloids, named ealamines A−H (4a, 4b, and 5−10)
(Figure 1), from the twigs and leaves of A. ealaensis. They were
discovered together with two known,3,23,31,32 likewise 7,8′-
linked metabolites, 6-O-demethylancistrobrevine A (11) and
yaoundamine A (12), which had earlier been identiﬁed in
related African Ancistrocladus species. Seven of the new
metabolites, ealamines A−G (4a, 4b, and 5−9), are the ﬁrst
naturally occurring 7,8′-coupled “hybrid-type” naphthyl-
Figure 1. Naphthylisoquinoline alkaloids from the Central African liana A. ealaensis, among them a series of 10 compounds with the rare 7,8′-
coupling type: the new ealamines A−H (4a, 4b, 5−10) and the known31,32 alkaloids 6-O-demethylancistrobrevine A (11) and yaoundamine A
(12), the latter two now detected for the ﬁrst time in A. ealaensis; likewise shown are the previously identiﬁed dimer ealapasamine C (1),10 a cross-
coupling product of a 5,8′- and a 7,8′-linked naphthylisoquinoline, and the two 5,8′-coupled monomeric alkaloids ancistroealaines A (2)9 and C
(3).11
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tetrahydroisoquinoline alkaloids. Prior to this isolation work,
only two 7,8′-linked hybrid-type alkaloids have been described,
viz., yaoundamine A (12) with a dihydroisoquinoline subunit
(here likewise detected in A. ealaensis) and its 6-O-rhamnoside
analogue, yaoundamine B, from the Cameroonian liana A.
korupensis.32
The elucidation of the axial conﬁguration of the new hybrid-
type 7,8′-coupled naphthyltetrahydroisoquinolines with R-
conﬁguration at C-3 by 2D NMR measurements proved to
be unexpectedly challenging, since the energetically preferred
conformers of the tetrahydropyrido parts of the M-conﬁgured
alkaloids ealamines B (4b) and C (5) were found to adopt an
arrangement with both the nitrogen atom and C-3 being
“down”, and not, as in other investigated cases,6,19 a half-chair
conformation, i.e., with the nitrogen atom “up” and C-3
“down”. This led to unexpected cross-peaks in the NOESY
spectra, which seemed to be contradictory to the ones
anticipated for 4b and 5 regarding the initially assumed half-
chair conﬁrmation of their tetrahydroisoquinoline portions.
Here we describe the application of quite time-demanding, yet
selective NOESY experiments with mixing-time optimization,
which ﬁnally permitted reliable conﬁgurational assignments of
such 7,8′-linked hybrid-type alkaloids with an M-conﬁguration
at the axis, by diagnostically decisive long-range couplings
across the biaryl axis. The assignment of the absolute axial
conﬁgurations of the ealamines A−H (1a, 1b, and 5−10), as
obtained by 2D NMR measurements, was conﬁrmed by
density functional theory (DFT) calculations of their
minimum structures and by comparison of the experimental
electronic circular dichroism (ECD) data with the calculated
ones.
Furthermore, as part of our ongoing studies on the anti-
infect ive potential of naphthyl isoquinoline alka-
loids,1,9−13,19−27,30,31 the ealamines A−D (4a, 4b, 5, and 6)
were tested for their activities against protozoan parasites
causing severe tropical diseases such as malaria tropica,
Chagas’ disease, African sleeping sickness, and leishmaniasis.
In addition, they were investigated for their cytotoxic eﬀects
against PANC-1 human pancreatic cancer cells under nutrient-
deprived conditions.
■ RESULTS AND DISCUSSION
Isolation and Structural Elucidation of Naphthyliso-
quinoline Alkaloids. Leaves and twigs of A. ealaensis were
collected in the Eala Botanical Garden (Jardin Botanique
d’Eala) near the town of Mbandaka in the northwestern part of
the Democratic Republic of the Congo. The air-dried material
was ground and exhaustively extracted with MeOH. After
evaporation of the solvent, the crude extracts were macerated
with water and then further processed by liquid−liquid
partition using n-hexane and CH2Cl2. Fractionation of the
CH2Cl2 layers by column chromatography (CC) and solid-
phase extraction (SPE) using C18 reversed-phase silica gel
provided several alkaloid-containing subfractions, which were
subjected to preparative HPLC, permitting isolation of 10 pure
compounds (Figure 1).
One of the metabolites identiﬁed in the twig extract was the
known 7,8′-coupled alkaloid 6-O-demethylancistrobrevine A
(11), which had earlier been detected in the West African liana
A. abbreviatus3,31 and in a botanically undescribed Congolese
Ancistrocladus species.23 With its S-conﬁguration at C-3 and an
oxygen function at C-6, this naphthyltetrahydroisoquinoline
belongs to the subclass of Ancistrocladaceae-type naphthyliso-
quinolines. Besides 11, the likewise 7,8′-linked, but hybrid-type
naphthyldihydroisoquinoline yaoundamine A (12), previously
only known to occur in A. korupensis,32 was isolated from the
twigs and leaves of A. ealaensis. All of the eight other
naphthylisoquinoline alkaloids discovered in the MeOH/
CH2Cl2 extracts of A. ealaensis are new.
Ealamine A (4a). According to the HRESIMS, the
molecular formula of the ﬁrst new metabolite, obtained as a
brownish powder from an alkaloid-enriched subfraction of the
leaf extract, was determined as C25H30NO4 (m/z 408.21570,
[M + H]+). The 13C NMR and DEPT-135 spectra indicated
the presence of 25 nonequivalent carbon atoms, among them
16 aromatic ones. Comprehensive analysis of the 1H and 13C
NMR data (Table 1) revealed the presence of a substituted
naphthalene spin system with four aromatic methines, H-1′
(δH 6.85), H-3′ (δH 6.78), H-6′ (δH 6.94), and H-7′ (δH 7.21),
two methoxy functions, MeO-4′ (δH,C 3.93, 57.1) and MeO-5′
(δH,C 3.96, 56.9), and one aromatic methyl group, Me-2′ (δH,C
2.31, 22.2). An additional spin system corresponding to a
tetrahydroisoquinoline subunit was assigned according to a
shielded aromatic proton at δH 6.56 (H-5), two unshielded
aliphatic methines at δH 4.72 (H-1) and 3.87 (H-3), two
diastereotopic protons, Heq-4 (δH 3.15) and Hax-4 (δH 2.88),
one shielded aromatic methoxy group, MeO-8 (δH,C 3.07,
60.8), and two methyl groups, Me-1 (δH,C 1.65, 19.6) and Me-
3 (δH,C 1.51, 19.4) (Figure 2A). The normal, not high-ﬁeld-
shifted signal of Me-2′ (δH 2.31) excluded the biaryl axis from
being located at C-1′ or C-3′, thus leaving only C-8′ and C-6′
Table 1. 1H (600 MHz) and 13C (150 MHz) NMR Data of
Ealamines A (4a) and B (4b) in Methanol-d4 (δ in ppm)
ealamine A (4a) ealamine B (4b)
no. δH (J in Hz) δC, type δH (J in Hz) δC, type
1 4.72, q (6.8) 50.1, CH 4.73, q (6.8) 50.0, CH
3 3.87, m 45.3, CH 3.88, m 45.3, CH
4eq 3.15, dd (17.5,
4.8)
34.6, CH2 3.20, dd (17.9,
4.9)
34.6, CH2
4ax 2.88, dd (17.5,
11.9)
2.88, dd (17.9,
11.7)
5 6.56, s 111.3, CH 6.56, s 111.3, CH
6 157.7, C 157.8, C
7 121.7, C 121.7, C
8 157.6, C 157.6, C
9 118.7, C 118.6, C
10 133.0, C 133.0, C
1′ 6.85, d (1.1) 119.2, CH 6.84, d (1.1) 119.2, CH
2′ 137.7, C 137.7, C
3′ 6.78, d (1.4) 109.9, CH 6.78, d (1.2) 109.9, CH
4′ 158.7, C 158.7, C
5′ 158.7, C 158.7, C
6′ 6.94, d (8.1) 106.7, CH 6.95, d (8.1) 106.7, CH
7′ 7.21, d (8.0) 130.9, CH 7.21, d (8.1) 131.0, CH
8′ 124.6, C 124.5, C
9′ 137.7, C 137.7, C
10′ 117.5, C 117.5, C
CH3-1 1.65, d (6.8) 19.6, CH3 1.65, d (6.8) 19.6, CH3
CH3-3 1.51, d (6.3) 19.4, CH3 1.51, d (6.3) 19.5, CH3
OCH3-8 3.07, s 60.8, CH3 3.07, s 60.8, CH3
CH3-2′ 2.31, s 22.2, CH3 2.31, s 22.2, CH3
OCH3-4′ 3.93, s 57.1, CH3 3.93, s 57.1, CH3
OCH3-5′ 3.96, s 56.9, CH3 3.96, s 56.9, CH3
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as the coupling positions. The NOESY correlation sequence in
the series {MeO-5′ ↔ H-6′ ↔ H-7′} showed that C-6′ could
not be the axis-bearing carbon atom, thus revealing that the
naphthalene portion is coupled via C-8′. This assignment was
proven by HMBC interactions from H-1′ to the quaternary
carbon atom C-8′ (δC 124.6) and from H-7′ to C-9′ (δC
137.7) and C-5′ (δC 158.7). The attribution of H-1′ and H-3′,
in turn, was deduced from the NOESY correlation sequence
{H-1′ ↔ Me-2′ ↔ H-3′ ↔ MeO-4′} and from HMBC
interactions, each, from H-1′ and H-3′ to C-2′ (Figure 2B). A
NOESY correlation between H-5 and Heq-4 and HMBC
interactions of H-5 to C-4 suggested the presence of a
tetrahydroisoquinoline portion with no substituent at C-5, thus
leaving the coupling position to be located at C-7. This result
was conﬁrmed by a series of further C−H correlations
involving C-7 and C-8′: C-7 exhibited a 3J interaction with
H-5 in the tetrahydroisoquinoline subunit and a 4J correlation
with H-7 across the biaryl axis, while, vice versa, C-8′ displayed
3J couplings to H-6′ and H-10′ and a 4J HMBC interaction
with H-5 (Figure 2B).
From a NOESY correlation between Me-1 (δH 1.65) and H-
3 (δH 3.87), the relative conﬁguration at C-1 versus C-3 in the
tetrahydroisoquinoline part (Figure 2C) was deduced to be
trans. The absolute conﬁgurations at C-1 and C-3 were
determined by ruthenium-mediated oxidative degradation as
described earlier,35 with ensuing stereochemical analysis of the
resulting amino acids by gas chromatography with mass-
selective detection (GC-MSD) after derivatization with the R-
enantiomer of Mosher’s acid chloride. The formation of R-3-
aminobutyric acid and D-alanine established the new alkaloid
to be R-conﬁgured at both C-1 and C-3. The conﬁguration at
the biaryl axis relative to the stereogenic centers was deduced
from a long-range NOESY interaction between H-7′ and Me-1,
indicating that these two spin systems are on the same side of
the isoquinoline plane, which, in conjunction with the R-
conﬁguration at C-3, should be the upper side, so that the
biaryl axis should be P-conﬁgured, as illustrated in Figure 2C.
This stereochemical attribution was conﬁrmed by the
complementary NOESY correlation between H-1′ and H-1,
which were, thus, both on the bottom side of the molecule.
The axial P-conﬁguration was corroborated by the ECD
spectrum of the new metabolite displaying a negative Cotton
eﬀect at 213 nm (Δε, −13.3) and a positive one at 257 nm
(Δε, +8.4), which was in accordance with the ECD curve of
the known, likewise 7,8′-coupled and P-conﬁgured−and co-
occurring−alkaloid 6-O-demethylancistrobrevine A (11)23,31
(Figure 2D). The new naphthylisoquinoline was thus found to
be 1R,3R,7P-conﬁgured and, consequently, possesses the full
absolute stereostructure 4a as outlined in Figure 1. Owing to
its isolation from A. ealaensis, it was given the name ealamine
A.
The constitution and the relative conﬁguration of ealamine
A (4a) were additionally conﬁrmed by single-crystal X-ray
diﬀraction analysis (Figure 3). Naphthylisoquinoline alkaloids
are usually diﬃcult to crystallize without prior chemical
derivatization,28,36 and only very few X-ray structure analyses
have so far succeeded.21,28,36,37 In the case of 4a, crystals of
suitable quality were obtained by slow diﬀusion of n-hexane
into a solution of 4a in acetone at room temperature in the
presence of triﬂuoroacetic acid. The crystal structure of
ealamine A (4a) in its N-protonated form (triﬂuoroacetate,
TFA salt), together with one molecule of acetone, as illustrated
in Figure 3, fully conﬁrmed the anticipated constitution and
relative conﬁguration of this new alkaloid as established above.
Furthermore, based on the results of the oxidative degradation,
the X-ray diﬀraction analysis ﬁrmly corroborated 4a to be
1R,3R,7P-conﬁgured. It also showed the expected half-chair
conformation in the heterocyclic tetrahydropyrido ring, with
H-3 and the methyl group at C-1 in axial positions, while Me-3
and H-1 were equatorial.
Ealamine B (4b). HRESIMS analysis of the second
compound isolated from the same leaf subfraction containing
Figure 2. (A) Selected 1H and 13C NMR shifts (in methanol-d4, δ in
ppm) of ealamine A (4a), (B) key NOESY (double blue arrows) and
HMBC (single orange arrows) interactions indicative of the
constitution of 4a, (C) decisive NOESY correlations (double blue
arrows) deﬁning the relative conﬁguration of 4a at the stereogenic
centers versus the biaryl axis, and (D) absolute axial conﬁguration of
4a assigned by comparison of its ECD spectrum with that of the
known23,31 related 7,8′-coupled alkaloid 6-O-demethylancistrobrevine
A (11).
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ealamine A (4a), yet occurring in distinctly lower quantities
and eluting more rapidly on the RP18 material, gave a
molecular formula of C25H29NO4, i.e., the same as 4a. The new
metabolite exhibited proton signals with coupling patterns and
coupling constants in the 1H NMR spectrum (Table 1) almost
identical to those of 4a, thus suggesting that the compound is a
stereoisomer of 4a. Like for compound 4a, it was again a 7,8′-
coupled naphthyltetrahydroisoquinoline, as deduced from
HMBC interactions from H-7′ (δH 7.21) to C-7 (δC 121.7)
and from H-1′ (δH 6.84) to C-8′ (δC 124.5). This was
evidenced further by the upﬁeld-shifted signal of MeO-8 (δH
3.07), from an NOE cross-peak from H-4eq (δH 3.20) to a
singlet at δH 6.56, which had to be H-5, and from NOESY
correlations between MeO-8 and H-1′ and between MeO-8
and H-7′. Moreover, similar to 4a, the new compound
possesses two O-methyl groups (δH 3.93 and 3.96) at C-4′ and
C-5′ in the naphthalene subunit, as deduced from NOESY
interactions to H-3′ (δH 6.78) and H-6′ (δH 6.95), respectively.
The fourth oxygen function thus had to be a free phenolic
hydroxy group at C-6 in the isoquinoline part. Hence, the
isolated metabolite had the same constitution as 4a, yet being
conﬁgurationally diﬀerent.
A NOESY cross-peak of the protons of Me-1 (δH 1.65) to
H-3 (δH 3.88) was used to assign the methyl groups at C-1 and
C-3 as trans to one another (Figure 5, bottom). The oxidative
degradation35 procedure again delivered only D-alanine and R-
3-aminobutyric acid, and, thus, together with the relative trans-
conﬁguration, the absolute conﬁgurations of the two stereo-
genic centers in the tetrahydroisoquinoline subunit wereas
in the case of 4aattributed as 1R,3R. Hence, ealamine A (4a)
and the new naphthylisoquinoline alkaloid were most likely a
pair of atropo-diastereomers. Accordingly, the second new
metabolite should be M-conﬁgured at the biaryl axis.
Comparison of the ECD spectrum of the new alkaloid with
that of ealamine A (4a) revealed these two compounds to
display an opposite curve around 225 nm (see gray zone and
dotted line in Figure 4). Remarkably, the negative Cotton
eﬀect at 230 nm (Δε, −15.8) monitored for the new alkaloid
was quite strong compared to the weak positive one at 225 nm
(Δε, +3.8) observed for 4a. This opposite ECD behavior of
the two alkaloids in the decisive part of the spectrum for the
biaryl chromophore supported the assumption that the second
metabolite isolated from the leaf extract of A. ealaensis should
be M-conﬁgured, thus possessing the structure 4b (see Figure
1). For other wavelengths, the ECD curves of 4a and 4b,
however, showed diﬀerent, not fully reversed shapes. In many
cases,1−3,21,27,31 the ECD spectra of atropo-diastereomers are
virtually opposite of each other, because the chiroptical
behavior is largely dominated by the stronger biaryl
chromophore and, thus, by the axial conﬁguration. On the
other hand, since the two apparently atropisomeric naph-
thylisoquinoline alkaloids4a and 4bwere diastereomers
and not enantiomers, the appearance of nonopposite, but
divergent ECD spectra should not be totally excluded.38
Apparently, the chromophore-related parts of the molecules
were not fully mirror-image-like in this case, probably as a
consequence of conformational divergences concerning the
dihedral angles at the axes of these two alkaloids due to the
diﬀerent relative conﬁgurations in these two atropo-diastereo-
meric alkaloids.
The assignment of the absolute axial conﬁguration of the
new compound 4b to beM was in agreement with a long-range
NOESY correlation between Me-2′ (δH 2.31) and Me-1 (δH
1.65) (Figure 5, bottom). On the other hand, the likewise
expected cross-peak between H-1′ (δH 6.84) and Me-1 was not
found in the NOESY spectrum of 4b, but anotherseemingly
contradictorylong-range NOESY interaction between Me-1
and H-7′ (δH 7.21) was observed, the latter two spectroscopic
values apparently consistent with a P-conﬁguration, as in
ealamine A (4a). Suchat ﬁrst sight conﬂictinginteractions
had never been observed in any other naphthylisoquinoline
alkaloid before. A rational explanation resulted from a
comparative conformational analysis of 4a and 4b by DFT
calculations using the B3LYP-3D/def2-SVP method. These
investigations revealed that 4a occurred mainly in a half-chair
conformation 4a-I, i.e., with the nitrogen atom “up” and C-3
“down” (see Figure 5, top, center). The most populated
conformer of 4b, by contrast, was not the corresponding half-
chair form 4b-I (see Figure 5, bottom, left), but the
tetrahydroisoquinoline portion of the new compound 4b was
found to preferably adopt the conformation 4b-II (see Figure
5, bottom, center), with both the nitrogen and C-3 “down” and
with Me-1 now occupying a pseudoequatorial position and, in
Figure 3. ORTEP drawing of the crystal structure of ealamine A (4a)
as its triﬂuoroacetate (TFA) salt crystallized together with one
molecule of acetone per two molecules of 4a·TFA (carbon: gray;
nitrogen: blue; oxygen: red). The equatorial hydrogen, Heq, at the
nitrogen atom is linked via a hydrogen bond to the oxygen of a
triﬂuoroacetate anion, and the axial one, Hax, is likewise connected to
yet another triﬂuoroacetate anion, thus forming a chain F3C−CO−
O−···Heq−N+R2−Hax···−O−OC−CF3 in the crystal lattice, continued
by hydrogen bonding of the second oxygen function in the TFA
molecules to further ealamine molecules.
Figure 4. Comparison of the experimental ECD spectrum (monitored
in methanol) of ealamine B (4b) with that of eleamine A (4a). The
diagnostically decisive bandwidth around 225 nm is marked in gray.
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turn, with H-1 becoming pseudoaxial. Such a rarely observed
array has been referred to as a half-boat conformation in the
literature.39 With the Me-1 group in 4b-II in an equatorial
position, the spatial distance to H-1′ was largely increased (up
to ca. 4.7 Å), now, instead, permitting detection of an
unexpected long-range NOE interaction between Me-1 and H-
7′, which would not have been imaginable in the case of 4b-I.
For 4b-II, the steric position of H-1 was also in agreement with
the NOE correlation of H-1 (δH 4.73) to Hax-4 (δH 2.88), both
now occupying an axial position, with a relatively short
computed distance of 2.331 Å. These unexpected conforma-
tional peculiarities had never been observed before within this
class of alkaloids.
The calculations also showed that in the case of ealamine B
(4b), and diﬀerent from that of ealamine A (4a), H-1′ was
largely shielded by the methoxy group at C-8 and was, thus,
prevented from NOE interactions with Me-1. In consequence,
the two atropo-diastereomers 4a and 4b were clearly
distinguishable by the long-range NOESY interaction between
Me-1 and Me-2′, as found only in 4b, not in 4a (and not in any
other comparable naphthyltetrahydroisoquinoline). This cor-
relation had thus become the decisive one for an unambiguous
attribution of an M-conﬁguration at the biaryl axis of the 7,8′-
coupled naphthylisoquinoline alkaloid presented in this paper.
Accordingly, also in view of the fact that the new metabolite
4b had the same constitution as 4a and the same relative and
absolute conﬁgurations at the two stereocenters C-1 and C-3
in the tetrahydroisoquinoline subunit, this alkaloid was indeed
the atropo-diastereomer of 4a and, thus, had to be M-
conﬁgured at the biaryl axis, hence possessing the full absolute
stereostructure 4b as shown in Figure 1. It was named
ealamine B.
For a further conﬁrmation of the absolute conﬁgurations at
the biaryl axis of the ealamines A (4a) and B (4b), quantum-
chemical ECD calculations at the TD-CAM-B3LYP/def2-
TZVP(-f) level were performed. The ECD spectrum
theoretically predicted for the P,R,R-atropo-diastereomer was
in good agreement with the respective curve measured for
ealamine A (4a), and the spectrum calculated for the M,R,R-
atropo-diastereomer was in accordance with the experimental
ECD curve of ealamine B (4b) (Figure 6).
Ealamine C (5). The third metabolite isolated from the
leaves of A. ealaensis was obtained as an optically active
brownish powder. According to the HRESIMS, this corre-
sponded to a molecular formula of C24H27NO4. The most
signiﬁcant diﬀerence between the NMR data of the new
compound (Tables 2 and 3) when compared to those of 4a
and 4b was a missing O-methyl group. NOESY interactions
Figure 5. Divergent conformational equilibria in the partially saturated heterocyclic rings of ealamine A (4a) and ealamine B (4b), as evident from
DFT calculations of the molecular minimum structures of 4a and 4b and decisive NOESY interactions (double blue arrows) deﬁning the relative
conﬁguration at the stereogenic centers versus the biaryl axis of 4a and 4b. The single-point energy diﬀerence between the low-populated species
4b-I and the most stable one, 4b-II, was calculated as ΔE = 3 kcal/mol, leading to a slightly shifted population between these diﬀerent conformers
in favor of conformation type I for 4a and conformation type II for 4b.
Figure 6. Assignment of the absolute conﬁgurations of ealamine A
(4a) and its atropo-diastereomer ealamine B (4b) by comparison of
the experimental ECD curves (monitored in methanol) with the
spectra calculated for the P- and the M-atropo-diastereomers using
TD-CAM-B3LYP/def2-TZVP(-f).
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from H-3′ (δH 6.79) to MeO-4′ (δH 4.08) and from MeO-8
(δH 3.07) to H-1′ (δH 6.85) and to H-7′ (δH 7.16) revealed the
presence of a free phenolic hydroxy group, located at C-5′
(Figure 7A). Like in 4a and 4b, the relative conﬁguration of
the two methyl groups at C-1 versus C-3 was deduced to be
trans from speciﬁc NOE interactions, and again the absolute
conﬁgurations in the tetrahydroisoquinoline subunit were
assigned as 1R,3R by ruthenium-mediated oxidative degrada-
tion.35 ECD spectroscopy established the compound to be M-
conﬁgured at the biaryl axis (Figure 7C). Similar to ealamine B
(4b), an NOE cross-peak from Me-1 (δH 1.64) to Me-2′ (δH
2.32) was observed, along with interactions between Me-1 and
H-7′ (δH 7.16) and between H-1 (δH 4.72) and Hax-4 (δH
2.88) (Figure 7A), which were found to be indicative of an
axial M-conﬁguration. Calculations using the ORCA40 software
package gave rise to a preferential minimum structure of the
new metabolite showing the same unusual three-dimensional
arrangement in the tetrahydroisoquinoline subunit as found for
Table 2. 1H (600 MHz) NMR Data of Ealamines C−H (5−10) in Methanol-d4 (δ in ppm)
ealamine C (5) ealamine D (6) ealamine E (7) ealamine F (8) ealamine G (9) ealamine H (10)
no. δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz)
1 4.72, q (6.7) 4.90, q (6.9) 4.66, q (6.8) 4.77, q (6.9) 4.68, q (6.5) 4.60, q (6.9)
3 3.86, m 3.89, m 4.15, m 3.90, m 3.49, m 3.47, m
4eq 3.14, dd (17.8, 4.8) 3.16, dd (17.4, 5.6) 3.12, dd (18.8, 5.0) 3.22, dd (16.7, 4.5) 2.96, pd (7.5) 3.01, pd (7.05)
4ax 2.88, dd (17.6, 11.7) 2.86, dd (18.3, 11.7) 2.96, dd (18.8, 12.0) 2.96, dd (18.1, 11.7) 2.96, pd (7.5) 3.01, pd (7.05)
5 6.56, s 6.57, s 6.58, s 6.74, s 6.58, s 6.60, s
1′ 6.85, br s 6.80, br s 6.89, s 6.79, br s 6.85, br s 6.74, s
3′ 6.79, d (1.2) 6.79, s 6.79, s 6.76, d (1.2) 6.80, d (1.1) 6.66, d (1.3)
6′ 6.80, d (7.9) 6.94, d (8.0) 6.94, d (8.3) 6.94, d (8.1) 6.80, d (7.9) 6.95, d (8.1)
7′ 7.16, d (7.9) 7.22, d (8.0) 7.19, d (8.0) 7.18, d (7.9) 7.17, d (7.9) 7.19, d (8.0)
CH3-1 1.64, d (6.8) 1.65, d (6.8) 1.65, d (6.8) 1.68, d (6.9) 1.72, d (6.6) 1.75, d (6.7)
CH3-3 1.51, d (6.4) 1.51, d (6.5) 1.51, d (6.3) 1.55, d (6.5) 1.51, d (6.5) 1.60, d (6.5)
N-CH3 2.87, s 3.08, s
OCH3-6 3.15, s 3.64, s
OCH3-8 3.07, s 3.07, s 3.11, s 3.13, s 3.09, s
CH3-2′ 2.32, br s 2.31, s 2.31, s 2.31, br s 2.34, br s 2.27, br s
OCH3-4′ 4.08, s 3.96, s 3.93, s 3.95, s 4.09, s
OCH3-5′ 3.93, s 3.96, s 3.98, s 4.12, s
Table 3. 13C (150 MHz) NMR Data of Ealamines C−H (5−10) in Methanol-d4 (δ in ppm)
ealamine C (5) ealamine D (6) ealamine E (7) ealamine F (8) ealamine G (9) ealamine H (10)
no. δC, type δC, type δC, type δC, type δC, type δC, type
1 50.0, CH 49.8, CH 60.5, CH 50.0, CH 52.5, CH 62.8, CH
3 45.3, CH 45.3, CH 50.6, CH 45.3, CH 51.3, CH 60.9, CH
4 34.6, CH2 34.6, CH2 30.4, CH2 34.6, CH2 35.3, CH2 35.3, CH2
5 111.3, CH 111.5, CH 111.1, CH 111.3, CH 111.9, CH 111.2, CH
6 157.8, C 157.7, C 157.8, C 157.8, C 157.6, C 157.7, C
7 121.7, C 121.5, C 121.9, C 121.7, C 122.0, C 121.9, C
8 157.6, C 157.8, C 158.2, C 157.6, C 158.7, C 157.7, C
9 118.6, C 118.5, C 117.3, C 118.6, C 118.9, C 118.5, C
10 133.0, C 133.0, C 130.8, C 133.0, C 134.8, C 134.7, C
1′ 119.9, CH 119.4, CH 119.1, CH 119.9, CH 120,0, CH 117.6, CH
2′ 137.4, C 137.7, C 137.6, C 137.4, C 137.3, C 139.0, C
3′ 107.5, CH 109.9, CH 109.8, CH 107.5, CH 107.5, CH 113.1, CH
4′ 157.9, C 158.7, C 158.6, C 157.9, C 157.9, C 156.3, C
5′ 156.1, C 158.6, C 158.6, C 156.1, C 156.1, C 157.9, C
6′ 110.4, CH 106.5, CH 106.5, CH 110.4, CH 110.2, CH 104.5, CH
7′ 131.9, CH 130.9, CH 130.8, CH 131.9, CH 131.7, CH 130.4, CH
8′ 122.6, C 124.6, C 124.4, C 122.6, C 122.8, C 125.7, C
9′ 137.0, C 137.6, C 137.6, C 137.0, C 137.1, C 137.2, C
10′ 114.8, C 117.6, C 116.3, C 114.8, C 114.9, C 114.8, C
CH3-1 19.6, CH3 19.6, CH3 20.2, CH3 19.6, CH3 20.7, CH3 20.8, CH3
CH3-3 19.4, CH3 19.4, CH3 16.8, CH3 19.4, CH3 19.0, CH3 18.3, CH3
N-CH3 34.2, CH3 42.0, CH3
OCH3-6 61.1, CH3 56.9, CH3
OCH3-8 60.7, CH3 60.7, CH3 60.7, CH3 60.8, CH3 60.9, CH3
CH3-2′ 22.4, CH3 22.2, CH3 22.1, CH3 22.4, CH3 22.4, CH3 22.1, CH3
OCH3-4′ 56.9, CH3 56.9, CH3 56.9, CH3 56.9, CH3 56.9, CH3
OCH3-5′ 57.1, CH3 56.7, CH3 56.9, CH3 56.9, CH3
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4b, i.e., type II (see 4b-II in Figure 5), with both the nitrogen
atom and C-3 adopting a “down” position (Figure 7C). Again,
the half-chair conformation was not predominant. This
corroborated that such a previously unrecognized conforma-
tional preference of the tetrahydroisoquinoline portion, with
both the nitrogen atom and C-3 “down”, was linked to the
spatial orientation of the two chromophores within the series
of so far quite rare M-conﬁgured 7,8′-coupled naphthyl-
isoquinoline alkaloids.6,19,30 The new alkaloid thus possessed
the full stereostructure 5 (Figure 1) and was named ealamine
C.
Ealamine D (6). Along with ealamine C (5), a fourth
compound was isolated, albeit in very small quantities, with a
molecular formula identical to those of 4a and 4b. 1H (Table
2) and 13C NMR (Table 3) data and speciﬁc NOE correlations
(see Figure 8A) revealed the presence of yet another
naphthyltetrahydroisoquinoline alkaloid belonging to the rare
7,8′-coupling type. When compared with 4a and 4b, it diﬀered
by its OH/OMe substitution pattern in the tetrahydro-
isoquinoline portion, possessing a methoxy group (δH 3.15)
at C-6 and a free phenolic hydroxy function at C-8. As for 4a
and 4b, a relative trans-conﬁguration between the two
stereocenters at C-1 and C-3 was evident from a NOESY
interaction between H-3 (δH 3.89) and Me-1 (δH 1.65). The
absolute conﬁgurations at the stereogenic centers, as
determined by oxidative degradation,35 were again R, both
for C-1 and C-3. From its nearly identical ECD spectrum
compared to that of 4b (see Supporting Information), the
isolated minor alkaloid had the same axial conﬁguration, yet,
merely for formal reasons, according to the Cahn−Ingold−
Prelog rules, now denoted as P-conﬁgured. This stereo-
chemical assignment was corroborated by the decisive long-
range NOE interaction between Me-1 and Me-2′ (δH 2.31)
like in 4b and 5. Now, however, due to the lacking 8-O-methyl
group as in the case of the previous examples, ealamines B
(4b) and C (5), also the characteristic cross-peak from Me-1
to H-1′ (δH 6.80) was observed for this new alkaloid (Figure
8A). Again, the DFT-optimized minimum structure of the
isolated metabolite displayed a conformation of type II (see
4b-II in Figure 5) for the most populated conformer, with H-
1′, Me-1, and H-3 being located on the same side of the
molecule (Figure 8B). The new alkaloid thus possessed the
absolute stereostructure 6 (Figure 1). It was named ealamine
D.
Ealamines E (7) and F (8). The ﬁfth and the sixth new
alkaloids, also isolated from the leaves of A. ealaensis, showed
1H and 13C NMR data suggesting the presence of naphthyl-
tetrahydroisoquinoline alkaloids again belonging to the 7,8′-
coupling type. Their constitutions strongly resembled that of
the above-presented ealamine A (4a), yet with a higher degree
of methylation. According to the HRESIMS, both compounds
corresponded to a molecular formula of C26H31NO4. The
1H
NMR spectrum (Table 3) of the ﬁfth compoundin contrast
to that of 4ashowed four methyl groups, resonating at δH
1.51, 1.65, 2.31, and 2.87. The latter signal was typical of an N-
methyl group, while the NOESY correlation series {Heq-4 ↔
H-5↔ OMe-6} clearly revealed the sixth compound to possess
a methoxy function at C-6 (δH 3.64).
By the above-mentioned methodsthe oxidative degrada-
tion, speciﬁc NOESY interactions across the biaryl axis, DFT
calculations of the minimum structure, and ECD spectroscopy
(see Supporting Information)the two new alkaloids were
established to be R-conﬁgured, at both C-1 and C-3, and P-
conﬁgured at the axis, similar to ealamine A (4a). The ﬁfth
metabolite had the complete stereostructure 7 (Figure 1). It
was found to be a new N-methyl analogue of 4a and was
named ealamine E. The sixth alkaloid, which is the 6-O-methyl
Figure 7. (A) Key NOESY (double black arrows) interactions indicative of the constitution of ealamine C (5) and decisive NOESY correlations
deﬁning its relative conﬁguration at the stereogenic centers C-1 and C-3 in the tetrahydroisoquinoline subunit versus the biaryl axis (double blue
arrows), (B) DFT-optimized structure of 5, as obtained from calculations using the B3LYP-D3/def2-SVP method, and (C) conﬁrmation of the
absolute axial conﬁguration of 5 by comparison of its experimental ECD spectrum with that of ealamine B (4b).
Figure 8. (A) Decisive NOESY (double blue arrows) cross-peaks
proving the relative conﬁguration of ealamine D (6) at the biaryl axis
and at the stereogenic centers C-1 and C-3 in the tetrahydro-
isoquinoline part. (B) DFT-optimized structure of 6, based on the
B3LYP-D3/def2-SVP method.
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analogue of 4a, had the structure 8 (Figure 1); it was likewise
new and was given the name ealamine F.
Ealamine G (9). The seventh new alkaloid was isolated
from the twigs of A. ealaensis. It was obtained as an optically
active yellowish powder. According to HRESIMS and NMR
analysis, it had the same molecular formula of C24H27NO4 as
the above-described ealamine C (5) and the same constitution.
From an NOE correlation between H-1 (δH 4.68) and H-3 (δH
3.49), the relative conﬁguration at C-1 versus C-3 was deduced
to be cis (see Supporting Information). The formation of R-3-
aminobutyric acid in the oxidative degradation proved the new
metabolite to be R-conﬁgured at C-3. Given the relative cis-
conﬁguration at C-1 and C-3 in the tetrahydroisoquinoline
moiety, this indicated C-1 to be S-conﬁgured. NOESY
interactions between Me-1 (δH 1.72) and H-1′ (δH 6.85),
and between H-1 (δH 4.68) and H-7′ (δH 7.17), in conjunction
with the R-conﬁguration at C-3, etablished the biaryl axis to be
P-conﬁgured. This was conﬁrmed by the nearly identical ECD
spectrum of the new alkaloid compared to that of the likewise
P-conﬁgured ealamine A (4a) (see Supporting Information).
As a consequence, the new compound had the stereostructure
9 as displayed in Figure 1. It was, hence, the 1,7-di-epi-analogue
of the co-occurring ealamine C (5) and named ealamine G.
Ealamine H (10). A further new metabolite was isolated
from the twig extract of A. ealaensis, again obtained as an
optically active yellowish powder. As deduced by HRESIMS, it
had a molecular formula of C25H29NO4, identical to that of 4a.
Its 1H (Table 2) and 13C NMR (Table 3) spectra were very
similar to those of ealamine E (7). The 2D NMR correlations
indicated that the new metabolite possessed two methoxy
groups at C-8 and C-5′ andsimilar to 7an N-methyl group
in the tetrahydroisoquinoline part, as evidenced by NOE
correlations of the N-Me protons at δH 3.08 with the two
methyl doublets of C-1 and C-3. From a NOE correlation
between H-1 (δH 4.60) and H-3 (δH 3.47), the relative
conﬁguration of the methyl groups at C-1 versus C-3 was
deduced to be cis (Figure 9A). The oxidative degradation
procedure35 aﬀorded the S-enantiomer of N-methyl-3-amino-
butyric acid, thus establishing the absolute conﬁguration at C-3
as S, which, given the relative cis-conﬁguration, determined the
absolute conﬁguration at C-1 to be R. On the basis of this
absolute 1R,3S-stereoarray in the tetrahydroisoquinoline
portion, in combination with the observed long-range
NOESY cross-peaks between Me-1 (δH 1.75) and H-7′ (δH
7.19) and between H-1 (δH 4.60) and H-1′ (δH 6.74) (Figure
9A), the conﬁguration at the axis was assigned as P. The axial
P-conﬁguration was conﬁrmed by the ECD spectrum of the
new metabolite, which was in accordance with that of the co-
occurringand likewise P-conﬁguredealamine A (4a)
(Figure 9C). According to these ﬁndings, the new alkaloid
had the stereostructure 10 as presented in Figure 1. It was,
thus, the 3-epi-4′-O-demethyl analogue of ealamine E (7) and
named ealamine H. With its S-conﬁguration at C-3 and an
oxygen function at C-6 it was a typical Ancistrocladaceae-
type1,3 compound. Within this series of ten 7,8′-linked
naphthylisoquinolines presented here, only one of the other
alkaloids isolated from A. ealaensis belonged to the subclass of
Ancistrocladaceae-type metabolites, viz., the known31,32 6-O-
demethylancistrobrevine A (11) (Figure 1), which had
previously been discovered in two Ancistrocladus species from
West and Central Africa.
Figure 9. (A) Key NOESY interactions deﬁning the relative conﬁguration of ealamine H (10) at the stereogenic centers C-1 and C-3 in the
tetrahydroisoquinoline portion and relative to the biaryl axis (decisive cross-peaks are marked in blue), (B) DFT-optimized structure of 10,
obtained from calculations using the B3LYP-D3/def2-SVP method, and (C) conﬁrmation of the absolute axial conﬁguration of 10 by comparison
of its experimental ECD spectrum with that of ealamine A (4a).
Table 4. Antiprotozoal Activities of Ealamines A (4a), B (4b), C (5), and D (6) against Pathogens of the Genera Plasmodium,
Trypanosoma, and Leishmania and Their Cytotoxicities against Rat Skeletal Myoblast (L6) Cells
IC50 [μM]
a
compound P. falciparum (NF54)b P. falciparum (K1)c T. cruzid T. brucei rhodesiensee L. donovanif L6 cells (cytotoxicity)g selectivity indexh
standard 0.008i 0.36i 3.6j 0.007k 0.43l 0.041m h
4a 6.3 1.6 73.4 9.8 170 9.1 5.6 (K1)
4b 4.9 1.4 122.8 7.8 53.4 20.9 15.0 (K1)
5 0.84 n.d. 102 9.4 >250 47.7 56.8 (NF54)
6 22.2 8.2 225 106 >250 >250 >30 (K1)
aThe IC50 values are the means of two independent assays; the individual values vary by a factor of less than 2.
bChloroquine-sensitive strain of P.
falciparum. cChloroquine- and pyrimethamine-resistant strain of P. falciparum. dTulahuen C4 strain of T. cruzi (amastigotes in L6 cells). eSTIB 900
strain of T. brucei rhodesiense (trypomastigotes). fMHOM-ET-67/L82 strain of L. donovani (axenic amastigotes). gMammalian host cells (rat
skeletal myoblast L6 cells). hThe selectivity index is calculated as the ratio of the IC50 values for the L6 cells to the IC50 data relative to P.
falciparum. iChloroquine. jBenznidazole. kMelarsoprol. lMiltefosine. mPodophyllotoxin.
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Antiprotozoal Activities of Ealamines A−D (4a, 4b, 5,
and 6). Some of the mono- and dimeric naphthylisoquinoline
alkaloids previously discovered in A. ealaensis have been found
to display promising antiprotozoal activities in vitro.9−12 Most
remarkable are the potent antileishmanial and antitrypanoso-
mal eﬀects9 of the monomer ancistroealaine A (2) (Figure 1)
and the antiplasmodial activities of the dimer ealapasamine C
(1) (Figure 1) against the chloroquine-resistant K1 strain of
Plasmodium falciparum (IC50 = 6.3 nM), combined with a very
low cytotoxicity (IC50 = 6.0 μM), giving rise to a selectivity
index (SI) of nearly 1000.10 In view of these ﬁndings, the new
ealamines A (4a), B (4b), C (5), and D (6) were likewise
tested for their in vitro activities against the pathogens causing
malaria (Plasmodium falciparum), Chagas’ disease (Trypanoso-
ma cruzi), human African sleeping sickness (Trypanosoma
brucei rhodesiense), and visceral leishmaniasis (Leishmania
donovani) (Table 4). Due to the lack of material, ealamines
E−H (6−10) were not tested.
The most signiﬁcant activities of the four new alkaloids were
found against P. falciparum parasites. Noteworthy were the
good inhibitory eﬀects of the two atropo-diastereomers
ealamines A (4a) and B (4b) against the K1 strain, though
not reaching the extraordinary activity of the dimer ealapas-
amine C (1). Interestingly, the inhibitory potential of the
atropisomeric alkaloids 4a and 4b against Plasmodium parasites
showed comparable values, both against the chloroquine-
sensitive NF54 strain, with IC50 values of 6.3 μM for 4a and
4.9 μM for 4b, and against the chloroquine-resistant K1 strain,
with IC50 values of 1.6 μM for 4a and 1.4 μM for 4b (Table 4).
All of the four tested alkaloids exerted only moderate
cytotoxicities against rat skeletal myoblast (L6) cells, thus
showing a structure-dependent speciﬁcity of their antiplasmo-
dial activities (Table 4). The ealamines A−D (4a, 4b, 5, and 6)
exhibited only weak or virtually no antitrypanosomal or
antileishmalial activities.
Preferential Cytotoxicity against PANC-1 Cells.
Pancreatic cancer remains one of the leading causes of
cancer-related mortality worldwide.41 Since the disease is
asymptomatic in the ﬁrst phase, this aggressive malignancy is
typically diagnosed only at an advanced stage, when most of
the patients already suﬀer from enhanced metastases.42 The
rapid development of resistance to most conventional
chemotherapeutic agents such as 5-ﬂuorouracil and gemcita-
bine is one of the main reasons for treatment failure, leading to
a poor prognosis and a low 5-year survival rate of less than
5%.41,43 The development of anticancer drugs based on novel
mechanisms for the pancreatic cancer treatment is thus
urgently needed.44
The new ealamines A−D and G (4a, 4b, 5, 6, and 9) and the
likewise 7,8′-coupled known32 alkaloid yaoundamine A (12)
were tested for their cytotoxic activities against the PANC-1
human pancreatic cancer cell line in normal, nutrient-rich
medium (Dulbecco’s modiﬁed Eagle’s medium, DMEM) and
in nutrient-deprived medium (NDM), following the anti-
austerity strategy.45,46 This approach aims at the search for
potent compounds for a targeted inhibition of the speciﬁc
ability of pancreatic cancer cells to tolerate nutrient and oxygen
deprivation. Human pancreatic cancer cells were found to be
able to modulate their energy metabolism, thus allowing them
to survive up to 72 h and proliferate even in the complete
absence of essential nutrients such as glucose, amino acids, and
serum.46 Compounds displaying preferential cytotoxicity in
NDM without exhibiting cytotoxicity in DMEM are therefore
considered to be antiausterity agents.18,46−49 The data in Table
5 are given as preferential cytotoxicity (PC50) values,
representing the concentrations of the investigated compounds
at which 50% of the pancreatic cancer cells are killed in NDM
without apparent toxicity in DMEM.
All of the 7,8′-coupled naphthylisoquinolines examined here
displayed moderate to strong preferential cytotoxicities against
PANC-1 cancer cells in a concentration-dependent manner,
with PC50 values ranging from 9.9 to 60.4 μM (Table 5).
Within this series of alkaloids, the two new ealamines A (4a)
and C (5) were found to be the most potent representatives,
with PC50 values of 12.5 and 9.9 μM, respectively (Figure 10),
and thus exhibiting preferential cytotoxic activities comparable
to those of the most active monomeric alkaloids previously
discovered in related West and Central African species, yet
belonging to the subgroups of 5,8′- or 5,1′-linked naphthyl-
isoquinolines. The test results indicated that the degree of O-
methylation in the naphthalene subunit may signiﬁcantly aﬀect
the cytotoxic properties of the compounds, as seen from the
only moderate antiausterity eﬀect induced by ealamine B (4b)
(PC50, 30.6 μM) compared to the signiﬁcantly stronger eﬀect
exerted by its 5′-O-demethyl analogue ealamine C (5) (PC50,
9.9 μM). This tendency was also supported by the quite weak
preferential cytotoxicity of ealamine D (6) (PC50, 60.4 μM),
equipped with two O-methyl groups in the naphthalene unit.
The nearly similar PC50 values (33.4 and 37.8 μM) of ealamine
G (9) and yaoundamine A (12) suggested that the degree of
hydrogenation in the isoquinoline portion had no signiﬁcant
inﬂuence on the cytotoxicity of the compounds, whereas axial
chirality seemed to be of crucial importance: Ealamine A (4a)
(PC50, 12.5 μM) exerted a much stronger cytotoxic eﬀect
toward PANC-1 cells than its atropo-diastereomer ealamine B
(4b) (PC50, 30.6 μM).
Ealamine C (5), as the most potent compound, was further
investigated for its eﬀects on cell morphology and apoptosis
using the ethidium bromide (EB)−acridine orange (AO)
double-staining ﬂuorescence assay. AO and EB are both DNA
intercalating dyes, but they diﬀer in their ability to penetrate
into the cell. While AO can easily pass the membrane, EB can
penetrate only when the membrane integrity is lost during the
cell death process. As such, the living cell emits the bright
green ﬂuorescence due to AO, whereas dead or dying cells
emit predominantly red ﬂuorescence due to EB. As shown in
Figure 11, the morphology of human PANC-1 cells remained
intact even when exposed to complete nutrient deprivation for
24 h and due to AO emitted green ﬂuorescence exclusively.
Treatment with ealamine C (5), on the other hand, resulted in
a noticeable alteration of the PANC-1 cell morphology in a
concentration-dependent manner. Treatment with 12.5 μM
ealamine C (5) led to both EB- and AO-stained cells,
Table 5. Preferential Cytotoxicity of Ealamines A (4a) B
(4b), C (5), D (6), and G (9) and Yaoundamine A (12) on
Human Pancreatic Cancer PANC-1 Cells in NDM
compound PC50 (in μM)
a compound PC50 (in μM)
a
4a 12.5 9 33.4
4b 30.6 12 37.8
5 9.9
6 60.4 arctigeninb 0.8
aConcentration at which 50% of cells were killed preferentially in
NDM. bUsed as reference compound.
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suggesting the loss of membrane integrity and cell death
processes. However, addition of 25 μM 5 caused a complete
swelling and rounding of PANC-1 cell morphology, giving rise
to red ﬂuorescence exclusively. All this evidence suggested that
ealamine C (5) is a promising antiausterity agent having the
ability to kill PANC-1 human pancreatic cancer cells
preferentially under nutrition starvation conditions.
Concluding Remarks. In summary, an unusually broad
series of ten 7,8′-coupled naphthylisoquinoline alkaloids were
discovered in the leaves and twigs of the Central African liana
A. ealaensis, among them eight new compounds, ealamines A−
H (4a, 4b, and 5−10), all of them oxygenated at C-6. While
only one of the new compounds, ealamine H (10), was a
typical Ancistrocladaceae-type metabolite, i.e., with S-conﬁg-
uration at C-3, seven of them represented the ﬁrst 7,8′-linked
naphthyltetrahydroisoquinolines with R-conﬁguration at C-3,
thus belonging to the mixed Ancistrocladaceae/Dioncophylla-
ceae-hybrid type. The elucidation of the absolute axial
conﬁguration of the latter turned out be unexpectedly
challenging due to their unprecedented conformational
behavior and required selective and time-demanding NOESY
experiments with mixing-time optimization. The NOE cross-
peak between Me-1 and Me-2′ was recognized to be the one
decisive for a reliable identiﬁcation of 7,8′-coupled hybrid-type
alkaloids with an M-conﬁguration at the axis. This is based on
the fact that the energetically preferred conformers of 7,8′-
coupled alkaloids with the combination M-conﬁguration at the
axis and R at C-3and, in particular if equipped with a
shielding methoxy group at C-8 like ealamine B (4b)were
found to adopt a conformational arrangement of the
tetrahydropyrido ring system with both the nitrogen atom
and C-3 being located ”up”, and not, as in other investigated
cases,6,19 occupying a half-chair array. These structural
pecularities were conﬁrmed by DFT calculations of the
minimum structures of the new ealamines.
Remarkably, the decisive Cotton eﬀects displayed by 7,8′-
coupled naphthylisoquinolines were weaker than those exerted
in 5,8′-coupled alkaloids, in particular in the case of the P-
conﬁgured compounds, which showed very small positive
Cotton eﬀects around 220 nm. This weak ECD eﬀect now
explained why in the case of the mixed-coupled dimers, such
as, ealapasamine C (1) (Figure 1), which consist of a 5,8′- and
a 7,8′-linked monomeric half, the overall ECD spectra were
always dominated by the strong eﬀects of the korupensamine-
like, 5,8′-coupled moieties.10 Another highlight of this study is
the X-ray structure analysis of ealamine A (4a), which is one of
the few examples of naphthylisoquinoline alkaloid crystal
Figure 10. Preferential cytotoxic activities of ealamines A (4a) (A)
and C (5) (B) against the PANC-1 human pancreatic cancer cell line
in nutrient-deprived medium (NDM) and Dulbecco’s modiﬁed
Eagle’s medium (DMEM).
Figure 11. Morphological changes of PANC-1 cells induced by ealamine C (5) in comparison to untreated cells (i.e., the control) in nutrient-
deprived medium (NDM). PANC-1 tumor cells were treated with 5 at the indicated concentrations in NDM and incubated for 24 h. Cells were
stained with ethidium bromide (EB) and acridine orange (AO) and photographed under ﬂuorescence (red and green) and phase contrast (gray)
modes using an EVOS FL digital microscope.
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structures and even the very ﬁrst one for a 7,8′-linked
representative.
In many African and Asian Ancistrocladus species, mono- and
dimeric alkaloids with 5,8′-, 5,1′-, or 7,1′-biaryl linkages had so
far been found to dominate the metabolite pro-
ﬁles,1−3,9,11−18,20,21,24−29 whereas 7,8′-coupled naphthyl-
isoquinolines had only rarely been identiﬁed, and if so, mainly
occurring as minor metabolites.1,3,6,10,19,23,30−33
The discovery of such a large series of alkaloids with the
otherwise so scarce 7,8′-coupling type in A. ealaensis
demonstrates that this Central African liana occupies an
outstanding chemo- and geotaxonomic position within the
genus Ancistrocladus. This is also underlined by the special
ability of A. ealaensis to synthesize constitutionally unsym-
metric heterodimers like the ealapasamines A−C.10 Only the
Cameroonian species A. korupensis has so far been reported to
produce another mixed dimer with a related molecular scaﬀold,
viz., korundamine A,33 along with two 7,8′-coupled hybrid-type
monomers, yaoundamine A (12) and its 6-O-L-rhamnoside
analogue, named yaoundamine B.32
Furthermore, A. ealaensis has now become a promising
source of potent bioactive compounds, with interesting
antiprotozoal,9−12 antileukemic,11 and, as presented here,
also promising preferential cytotoxic activities against PANC-
1 human cancer cells. All these results warrant further studies
on the pharmacological potential of naphthylisoquinoline
alkaloids in general. This work is currently in progress.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
determined on a JASCO P-1020-polarimeter, UV spectra were
determined on a Shimadzu UV-1800 spectrophotometer, and ECD
measurements were performed under nitrogen on a JASCO J-715
spectrometer at room temperature, using spectrophotometric-grade
methanol. The ECD data were processed using SpecDis.50 1D and 2D
NMR spectra were monitored on Bruker AMX 400 and DMX 600
instruments, using methanol-d4 (δH 3.31 and δC 49.15 ppm) as the
solvent. Chemical shifts (δ) are reported in parts per million (ppm),
and coupling constants (J) are given in hertz (Hz). NMR signal
multiplicities are denoted as singlet (s), doublet (d), doublet of
doublets (dd), quartet (q), pseudoquartet (pq), or multiplet (m).
Spectra were acquired and processed using an ACD/NMR processor
(version 12.01) and the Topspin 3.2 software (Bruker Daltonics).
HRESIMS measurements were performed in positive mode on a
Bruker Daltonics micrOTOF-focus mass instrument. HPLC-DAD
investigations were conducted on a JASCO LC-2000 Plus series
system. For LC-MS analysis, an Agilent 1100 series system was used,
equipped with a binary high-pressure mixing pump, with a degasser
module, an autosampler, a 1100 series photodiode array (PDA)
detector (Agilent Technology), and an Esquire 3000 Plus ion-trap
mass spectrometer with an electrospray ionization interface (Bruker
Daltonics). GC-MSD was performed on a GCMS-QP 2010SE system
(Shimadzu). Preparative HPLC was carried out on a JASCO system
(PU-1580 Plus) in combination with UV/vis detection at 200−680
nm (JASCO MD-2010 Plus diode array detector) at room
temperature. For maceration, a mechanical shaker was used at 160
rpm (rotations per minute). All organic solvents were of analytical-
grade quality. Ultrapure water was obtained from an Elga Purelab
Classicsystem. (S)-MTPA was purchased from Sigma-Aldrich
(Steinheim, Germany).
Plant Material. Twigs and leaves of Ancistrocladus ealaensis J.
Leónard7,8 were collected at Eala Botanical Garden (Jardin Botanique
d’Eala, Mbandaka, Democratic Republic of the Congo) in August
2008 by one of us (V.M.), and in August 2015 by Mr. B. K. Lombe
(GPS coordinates 00°03.605 N, 018°.886 E). The material of 2015
was additionally authenticated by LC-DAD-MS to contain the same
metabolites as the one of 2008. Voucher specimens (Nos. 43 and 57)
have been deposited at the Herbarium Bringmann, University of
Würzburg.
Extraction and Isolation. Following a protocol described
previously,11 naphthylisoquinoline alkaloids were extracted from air-
dried leaves (600 g) by repeated maceration of the ﬁne-powdered
plant material in MeOH (four cycles of 24 h each) to give, after
removal of the solvent, a viscous solution. The extract was dissolved in
water and cleared from chlorophyll by extracting with n-hexane.
Liquid/liquid partitioning between water and CH2Cl2 provided an
alkaloid-enriched fraction (5.1 g), which was subjected to column
chromatography (CC) on C18 reversed-phase silica gel using a
gradient (0:50 → 50:0) of CH3CN and ultrapure water containing
0.05% TFA. Fractions F12 to F35 were further resolved on ﬁve Sep-Pak
C18 Plus Light cartridges coupled in series (adsorbent: 130 mg,
particle size: 55−105 μm), again using a gradient of CH3CN and
ultrapure water from 0 to 50% H2O in CH3CN.
Assisted by LC-MS and LC-UV analysis to search for metabolites
of interest, alkaloid-containing subfractions were subjected to HPLC
on a SymmetryPrep C18 column, 19 × 300 mm, 7 μm (Waters), using
a solvent system consisting of A (H2O, 0.05% TFA) and B (CH3CN,
0.05% TFA), with a linear gradient (0−12 min: 10−20% B, 35 min:
45% B, 37 min: 50% B, 40 min: 100% B, 44 min: 100% B), at a ﬂow
rate of 10 mL min−1. Further puriﬁcation of the collected compounds
was achieved by HPLC on a Chromolith SemiPrep RP-18e column,
100 × 10 mm (Merck), by applying the following gradient at a ﬂow
rate of 10 mL min−1: A (H2O, 0.05% TFA) and C (MeOH, 0.05%
TFA): 0−2 min: 10% C, 8 min: 30% C, 11 min: 35% C, 20 min: 40%
C, 25 min: 45% C, 27 min: 100% C, to aﬀord 18.5 mg of ealamine A
(4a) (retention time 11.1 min), 10.3 mg of ealamine B (4b)
(retention time 10.8 min), 11.1 mg of ealamine C (5) (retention time
13.2 min), 4.0 mg of ealamine D (6) (retention time 11.7 min), and
0.9 mg of ealamine E (7) (retention time 12.5 min). Two further
alkaloid-containing subfractions were resolved similarly, by prepara-
tive HPLC on a SymmetryPrep C18 column, using a linear gradient
solvent system consisting of A and B (0−5 min: 15% B, 6 min: 20% B,
20 min: 25% B, 30 min: 30% B, 37 min: 55% B), at a ﬂow rate of 10
mL min−1. Additional puriﬁcation steps of the collected compounds
were performed on a Chromolith SemiPrep RP-18e column, using a
linear gradient of solvents A and C: 30% C, 13 min: 40% C, 19 min:
55% C, 20 min: 100% C, 23 min: 100% C, at a ﬂow rate of 10 mL
min−1, to yield 0.7 mg of ealamine F (8) (retention time 12.9 min)
and 1.2 mg of yaoundamine A (12) (retention time 15.2 min).
Following a protocol described previously,11 ﬁne-powdered ma-
terial of air-dried twigs (ca. 300 g) of A. ealaensis was exhaustively
extracted with MeOH/CH2Cl2 (7:3) at room temperature to give 2.8
g of a crude residue, which was, after dissolution in MeOH/water,
subjected to liquid−liquid partition with n-hexane to remove
nonpolar compounds. CC on silica gel (deactivated with triethyl-
amine) using a gradient of CH2Cl2 and MeOH (80:20 → 20:80)
aﬀorded several alkaloid-containing subfractions, which were further
resolved by preparative reversed-phase HPLC on a SymmetryPrep
C18 column with a solvent system consisting of A (MeOH, 0.05%
TFA) and B (CH3CN, 0.05% TFA). Using a linear gradient (0−10
min 18% B, 13−25 min 20% B, 45 min 50% B, 48 min 100% B) at a
ﬂow rate of 20 mL min−1, 5.3 mg of ealamine G (9) (retention time
21.3 min), 3.1 mg of ealamine H (10) (retention time 19.6 min), and
3.4 mg of 6-O-demethylancistrobrevine A (11) (retention time 25.1
min) were obtained, along with 4.2 mg of yaoundamine A (12)
(retention time 31.3 min) and 10.0 mg of ealamine A (4a) (retention
time 22.5 min).
Ealamine A (4a): brownish, amorphous powder; [α]D
23 −15.0 (c
0.05, MeOH); UV (MeOH) λmax (log ε) 200 (5.9), 203 (6.9), 219
(4.6), 231 (5.6), 265 (0.5), 307 (1.2), 321 (1.0), 350 (0.2) nm; ECD
(c 0.10; MeOH) λmax (log ε) 213 (−13.3), 225 (+3.8), 236 (−1.5),
240 (+0.1), 244 (−0.4), 257 (+8.4), 284 (−7.3), 318 (+2.1), 322
(+2.1) nm; 1H NMR and 13C NMR see Table 1; HRESIMS m/z
408.21570 [M + H]+ (calcd for C25H30NO4, 408.21693).
Ealamine B (4b): yellowish, amorphous powder; [α]D
23 −15.0 (c
0.04, MeOH); UV (MeOH) λmax (log ε) 200 (4.1), 206 (4.6), 218
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(3.6), 231 (4.7), 265 (0.4), 307 (1.1), 321 (0.9), 350 (0.01) nm;
ECD (c 0.10, MeOH) λmax (log ε) 200 (+10.4), 214 (−8.6), 225
(−11.5), 230 (−15.6), 241 (0.0), 251 (+3.8), 284 (−3.5), 311 (+1.7),
349 (−0.7), 360 (+0.1) nm; 1H NMR and 13C NMR, see Table 1;
HRESIMS m/z 408.21610 [M + H]+ (calcd for C25H30NO4,
408.21693).
Ealamine C (5): brownish, amorphous powder; [α]D
23 −24.0 (c
0.07, MeOH); UV (MeOH) λmax (log ε) 200 (5.4), 205 (6.9), 218
(5.3), 231 (7.1), 260 (0.5), 307 (1.3), 321 (1.2), 333 (0.8), 350
(0.01) nm; ECD (c 0.20, MeOH) λmax (log ε) 200 (−25.6), 203
(−59.4), 215 8 + 7.6), 217 (−25.1), 222 (+1.7), 227 (−79.9), 232
(+8.1), 252 (+15.4), 285 (−9.3), 315 (+6.1), 360 (+0.5) nm; 1H
NMR and 13C NMR, see Tables 2 and 3; HRESIMS m/z 394.20194
[M + H]+ (calcd for C24H28NO4, 394.20128).
Ealamine D (6): yellowish, amorphous powder; [α]D
23 −17.0 (c
0.06, MeOH); UV (MeOH) λmax (log ε) 200 (6.0), 205 (6.4), 218
(5.0), 227 (4.8), 271 (1.3), 288 (1.1), 307 (1.1), 350 (0.4) nm; ECD
(c 0.01, MeOH) λmax (log ε) 200 (+4.9), 215 (−5.1), 219 (−5.9), 224
(−3.5), 232 (−5.9), 242 (+0.03), 247 (+0.8), 267 (−1.2), 287 (+0.2),
303 (−0.2), 314 (+0.7), 323 (+0.3), 332 (+0.7), 360 (−0.2) nm; 1H
NMR and 13C NMR, see Tables 2 and 3; HRESIMS m/z 408.21610
[M + H]+ (calcd for C25H30NO4, 408.21693).
Ealamine E (7): yellowish, amorphous powder; [α]D
23 −13.0 (c 0.02,
MeOH); UV (MeOH) λmax (log ε) 200 (4.2), 205 (5.9), 218 (5.1),
231 (6.3), 260 (0.1), 307 (1.2), 321 (1.0), 333 (0.3) nm; ECD (c
0.02, MeOH) λmax (log ε) 200 (+2.5), 211 (−0.2), 215 (+0.3), 233
(−1.5), 251 (+0.2), 284 (−1.3), 311 (+0.3), 323 (+0.3), 348 (+0.2)
nm; 1H NMR and 13C NMR, see Tables 2 and 3; HRESIMS m/z
422.23295 [M + H]+ (calcd for C26H32NO4, 422.23303).
Ealamine F (8): yellow, amorphous powder; [α]D
23 −15.0 (c 0.04,
MeOH); UV (MeOH) λmax (log ε) 200 (4.1), 206 (5.9), 217 (4.8),
230 (5.8), 261 (0.2), 307 (1.1), 321 (1.0), 333 (0.2) nm; ECD (c
0.06, MeOH) λmax (log ε) 200 (+9.8), 211 (−4.7), 219 (+2.9), 233
(−1.8), 242 (−0.3), 261 (−3.1), 310 (+0.4), 318 (+0.5), 352 (−0.3),
365 (−0.3) nm; 1H NMR and 13C NMR, see Tables 2 and 3;
HRESIMS m/z 422.23356 [M + H]+ (calcd for C26H32NO4,
422.23303).
Ealamine G (9): yellowish, amorphous powder; [α]D
23 −20.0 (c
0.08, MeOH); UV (MeOH) λmax (log ε) 200 (3.4), 205 (6.9), 218
(5.3), 231 (7.1), 260 (0.5), 307 (1.3), 321 (1.2), 333 (0.8), 350
(0.01) nm; ECD (c 0.09, MeOH) λmax (log ε) 200 (+1.07), 204
(−8.46), 210 (+8.32), 212 (+5.51), 213 (+8.15), 216 (+4.45), 221
(+9.58), 234 (−1.55), 257 (+21.07), 286 (−12.70), 335 (+0.24), 400
(0.0) nm; 1H NMR and 13C NMR, see Tables 2 and 3; HRESIMS
m/z 394.20180 [M + H]+ (calcd for C24H28NO4, 394.20128).
Ealamine H (10): yellowish, amorphous powder; [α]D
23 −14.0 (c
0.02, MeOH); UV (MeOH) λmax (log ε) 200 (2.3), 205 (5.3), 218
(5.2), 231 (8.1), 260 (0.3), 307 (1.3), 321 (1.2), 333 (0.8), 350
(0.01) nm; ECD (c 0.09, MeOH) λmax (log ε) 200 (+3.59), 207
(+2.57), 216 (+0.53), 224 (+1.41), 228 (+0.82), 235 (+0.75), 254
(+5.84), 283 (−5.63), 310 (+0.66), 337 (−0.24), 381 (−0.20) nm;
1H NMR and 13C NMR, see Tables 2 and 3; HRESIMS m/z
408.21640 [M + H]+ (calcd for C25H30NO4, 408.21693).
Oxidative Degradation. Ruthenium(VIII)-catalyzed periodate
degradation of ealamines A−H (4a, 4b, and 5−10), the derivatization
of the resulting amino acids, and the assignment of the absolute
conﬁgurations of 4a, 4b, and 5−10 in their tetrahydroisoquinoline
subunits by GC-MSD analysis were carried out following a protocol
developed earlier.35
X-ray Crystallographic Analysis of Ealamine A (4a). Single
crystals suitable for structural analysis were obtained by slow, gentle
diﬀusion of n-hexane into a solution of 4a in acetone at room
temperature in the presence of triﬂuoroacetic acid. The crystal data of
4a in its protonated form were collected at T = 100 K on a Bruker D8
Quest Kappa diﬀractometer using a Photon 100 CMOS detector and
multilayer mirror monochromated Cu Kα radiation (λ = 1.541 84 Å).
The structure was solved using direct methods, reﬁned with the
SHELXL software package,51 and expanded using Fourier techniques.
All non-hydrogen atoms were reﬁned anisotropically. Hydrogen
atoms were included in the calculations of the structural factors and
assigned to idealized geometric positions. Crystallographic data for 4a
have been deposited with the Cambridge Crystallographic Data
Centre (deposition number: CCDC 1939956). Copies of these data
can be obtained, free of charge, from the Cambridge Crystallographic
Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
Crystal data of 4a: (2 C27H30NO6F3·C3H6O), Mr = 1101.12,
crystal size 0.463 × 0.424 × 0.285 mm3, triclinic space group P1, a =
8.9167(7) Å, b = 11.8688(12) Å, c = 14.7500(15) Å, α = 68.987(6)°,
β = 73.430(7)°, γ = 77.232(7)°, V = 1384.3(2) Å3, Z = 1, ρcalcd =
1.321 g cm−3, μ = 0.900 mm−1, F(000) = 580, T = 100(2) K,
GooF(F2) = 1.051, R1 = 0.0277, wR2 = 0.0744 for I > 2σ(I), R1 =
0.0278, wR2 = 0.0745 for all data, 10 743 unique reﬂections [θ ≤
74.538°] with a completeness of 99.9% and 725 parameters, 3
restraints, Flack parameter, x = 0.053(13).
Computational Details. The computational ECD analysis has
been done as described in the literature.52 B3LYP-D3/def2-SVP53
conformational analyses and CAM-B3LYP/def2-TZVP(-f) TD
calculations were performed using ORCA 3.040 making use of the
chain-of-sphere approximation (RIJCOSX)54 and in the case of the
TD calculation the COSMO(methanol) keyword. Evaluation of the
results was done using SpecDis 1.7150 with a σ of 0.2 eV and a UV
shift of 25 nm for ealamine A (4a) and of 22 nm for ealamine B (4b).
Antiprotozoal Evaluation. Antiparasitic activities and cytotox-
icities of ealamines A (4a), B (4b), C (5), and D (6) (Table 4) were
determined in vitro according to well-established protocols, as
reported previously.55
Preferential Cytotoxicity Assay against PANC-1 Cells. The
ealamines A−D (4a, 4b, 5, and 6) (Table 5) were evaluated for their
preferential cytotoxicity against PANC-1 human pancreatic cancer
cells (RBRC-RCB2095 purchased from the Riken BRC cell bank) by
a procedure described previously.18,44,56
Morphological Assessment of Cancer Cells after Treatment
with Ealamine C (5). Following a protocol published earlier,18,20,44
PANC-1 cells were treated for 24 h with ealamine C (5) at diﬀerent
concentrations or without any agent (control) in NDM. Cell
morphology (Figure 11) was visualized after addition of EB/AO
using an EVOS FL digital microscope (20× objective).
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Brünnert, D.; Chatterjee, M.; Seo, E.-J.; Efferth, T.; Bringmann, G. J.
Nat. Prod. 2017, 80, 443−458.
(20) Li, J.; Seupel, R.; Bruhn, T.; Feineis, D.; Kaiser, M.; Brun, R.;
Mudogo, V.; Awale, S.; Bringmann, G. J. Nat. Prod. 2017, 80, 2807−
2817.
(21) Bringmann, G.; Zhang, G.; Büttner, T.; Bauckmann, G.; Kupfer,
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Hemmerling, M.; Burschka, C. Acta Crystallogr., Sect. C: Cryst. Struct.
Commun. 1991, 47, 1703−1705. (b) Bringmann, G.; Rübenacker, M.;
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Dreyer, M.; Bringmann, G. J. Org. Chem. 2004, 69, 8602−8608.
(39) Lukova,́ K.; Nesvadba, R.; Uhlikova,́ T.; Obenchain, D. A.;
Wachsmuth, D.; Grabow, J.-U.; Urban, S. Phys. Chem. Chem. Phys.
2018, 20, 14664−14670.
(40) Neese, F. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2012, 2, 73−
78.
(41) (a) Ansari, D.; Tingstedt, B.; Andersson, B.; Holmquist, F.;
Sturesson, C.; Williamson, C.; Sasor, A.; Borg, D.; Bauden, M.;
Andersson, B. Future Oncol. 2016, 12, 1929−1946. (b) Hidalgo, M. N.
Engl. J. Med. 2010, 362, 1605−1617.
(42) (a) Bardeesy, N.; DePinho, R. A. Nat. Rev. Cancer 2002, 2,
897−909. (b) Strimpakos, A.; Saif, M. W.; Syrigos, K. N. Cancer
Metastasis Rev. 2008, 27, 495−522.
(43) (a) Nath, S.; Daneshvar, K.; Roy, L. D.; Grover, P.; Kidiyoor,
A.; Mosley, L.; Sahraei, M.; Mukherjee, P. Oncogenesis 2013, 2,
No. e51. (b) Long, J.; Zhang, Y.; Yu, X.; Yang, J.; LeBru, D. G.; Chen,
C.; Yao, Q.; Li, M. Expert Opin. Ther. Targets 2011, 15, 817−828.
(44) (a) Garrido-Laguna, I.; Hidalgo, M. Nat. Rev. Clin. Oncol. 2015,
12, 319−334. (b) Teague, A.; Lim, K.-H.; Wang-Gillam, A. Ther. Adv.
Med. Oncol. 2015, 7, 68−84.
(45) Izuishi, K.; Kato, K.; Ogura, T.; Kinoshita, T.; Esumi, H. Cancer
Res. 2000, 60, 6201−6207.
(46) Awale, S.; Lu, J.; Kalauni, S. K.; Kurashima, Y.; Tezuka, Y.;
Kadota, S.; Esumi, H. Cancer Res. 2006, 66, 1751−1757.
(47) Magolan, J.; Coster, M. J. Curr. Drug Delivery 2010, 7, 355−
369.
(48) (a) Awale, S.; Ueda, J.; Athikomkulchai, S.; Abdelhamed, S.;
Yokoyama, S.; Saiki, I.; Miyatake, R. J. Nat. Prod. 2012, 75, 1177−
1183. (b) Ueda, J.; Athikomkulchai, S.; Miyatake, R.; Saiki, I.; Esumi,
H.; Awale, S. Drug Des., Dev. Ther. 2013, 8, 39−47.
(49) (a) Nguyen, H. X.; Do, T. N. V.; Le, T. H.; Nguyen, M. T. T.;
Nguyen, N. T.; Esumi, H.; Awale, S. J. Nat. Prod. 2016, 79, 2053−
2059. (b) Nguyen, N. T.; Nguyen, M. T. T.; Nguyen, H. X.; Dang, P.
H.; Dibwe, D. F.; Esumi, H.; Awale, S. J. Nat. Prod. 2017, 80, 141−
148. (c) Nguyen, H. X.; Nguye, M. T. T.; Nguyen, N. T.; Awale, S. J.
Nat. Prod. 2017, 80, 2345−2352. (d) Li, J.; Seupel, R.; Bruhn, T.;
Feineis, D.; Kaiser, M.; Brun, R.; Mudogo, V.; Awale, S.; Bringmann,
G. J. Nat. Prod. 2017, 80, 2807−2817.
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